Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-ABL1(T315I). The pivotal phase 2 Ponatinib Ph(+) ALL and CML Evaluation (PACE) trial evaluated efficacy and safety of ponatinib at a starting dose of 45 mg once daily in 449 patients with chronic myeloid leukemia (CML) o...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Cortes, Jorge E., Kim, Dong-Wook, Pinilla-Ibarz, Javier, le Coutre, Philipp D., Paquette, Ronald, Chuah, Charles, Nicolini, Franck E., Apperley, Jane F., Khoury, H. Jean, Talpaz, Moshe, DeAngelo, Daniel J., Abruzzese, Elisabetta, Rea, Delphine, Baccarani, Michele, Müller, Martin C., Gambacorti-Passerini, Carlo, Lustgarten, Stephanie, Rivera, Victor M., Haluska, Frank G., Guilhot, François, Deininger, Michael W., Hochhaus, Andreas, Hughes, Timothy P., Shah, Neil P., Kantarjian, Hagop M.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2018
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6071555/
https://ncbi.nlm.nih.gov/pubmed/29567798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-09-739086
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires